David Pendarvis - Resmed Global Officer

RMEA Stock  EUR 23.60  0.40  1.72%   

Insider

David Pendarvis is Global Officer of Resmed Inc DRC
Age 64
Phone858 836 5000
Webhttps://www.resmed.com

Resmed Management Efficiency

The company has return on total asset (ROA) of 0.1155 % which means that it generated a profit of $0.1155 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2352 %, meaning that it generated $0.2352 on every $100 dollars invested by stockholders. Resmed's management efficiency ratios could be used to measure how well Resmed manages its routine affairs as well as how well it operates its assets and liabilities.
Resmed Inc DRC has accumulated 765.33 M in total debt with debt to equity ratio (D/E) of 61.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Resmed Inc DRC has a current ratio of 2.02, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Resmed until it has trouble settling it off, either with new capital or with free cash flow. So, Resmed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Resmed Inc DRC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Resmed to invest in growth at high rates of return. When we think about Resmed's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

INSIDER Age

Briony CPADiamondRock Hospitality
52
Ben NelsonDiamondRock Hospitality
N/A
Troy FurbayDiamondRock Hospitality
56
Dustin ResnickDiamondRock Hospitality
N/A
Justin LeonardDiamondRock Hospitality
45
Mark BruggerDiamondRock Hospitality
53
Jeffrey CFADiamondRock Hospitality
52
William TennisDiamondRock Hospitality
68
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. RESMED CUFS10 is traded on Frankfurt Stock Exchange in Germany. Resmed Inc DRC (RMEA) is traded on Frankfurt Exchange in Germany and employs 8,160 people.

Management Performance

Resmed Inc DRC Leadership Team

Elected by the shareholders, the Resmed's board of directors comprises two types of representatives: Resmed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Resmed. The board's role is to monitor Resmed's management team and ensure that shareholders' interests are well served. Resmed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Resmed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Amy Wakeham, VP Communications
Brett Sandercock, Chief Officer
BE MBA, CEO Director
Robert Douglas, Pres COO
Vered Keisar, Chief Officer
AM AM, Founder Chairman
David Pendarvis, Global Officer
Kaushik Ghoshal, Pres Bus
Constance Bienfait, Director Relations
Urvashi Tyagi, Chief Officer

Resmed Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Resmed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Resmed Stock

Resmed financial ratios help investors to determine whether Resmed Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Resmed with respect to the benefits of owning Resmed security.